---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009653"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:53:34.211241+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEAYA lays out 2026 goals: darovasertib PFS data Q1, three Phase 3 trials, IDE849 registrational start

## Summary
- Topline PFS results from Phase 2/3 OptimUM-02 for darovasertib+crizotinib in 1L HLA*A2-negative mUM expected Q1 2026.
- Darovasertib to be in three randomized Phase 3 trials (OptimUM-02, -10, -11) across UM stages by H1 2026.
- IDE849 (DLL3 TOP1 ADC) registrational monotherapy study in SCLC/NEC targeted to start by end of 2026.
- IDE034 (B7H3/PTK7 ADC) Phase 1 dose escalation to begin Q1 2026; IDE892 (PRMT5) Phase 1 in Q1 2026.
- Cash of $1.1 billion as of Sep 30, 2025, expected to fund operations into 2030.

## SEC filing metadata
- accession: 0001193125-26-009653
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312526009653/0001193125-26-009653-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312526009653/d93674d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009653
- JSON: https://secwatch.observer/filing/0001193125-26-009653.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009653.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.